Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zenas BioPharma
Zenas BioPharma is developing immune-based therapies for autoimmune and rare diseases.
Biotech
Zenas, MBX, Bicara head to Nasdaq in hot day for biotech IPOs
It’s a busy Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Therapeutics all going public
James Waldron
Sep 13, 2024 5:25am
Zenas, Bicara set out to raise $180M-plus in separate IPOs
Sep 6, 2024 8:18am
Bicara, Zenas seek IPOs to push late-phase assets toward market
Aug 23, 2024 5:07am
Zenas bags $200M series C to reach a handful of key mAB readouts
May 7, 2024 7:00am
BIO announces new CEO—Chutes & Ladders
Dec 8, 2023 9:30am
BMS pays Zenas $50M for some rights to ex-Xencor autoimmune drug
Sep 5, 2023 7:29am
